Quantum Genomics raises €11M; Genzyme sees promising results in Cerdelga PhIII;

@FierceBiotech: Can Actavis deliver a promised $6B boost from this pipeline? More | Follow @FierceBiotech

@JohnCFierce: Heard it on the biotech grapevine? Drop me a line. Editor's corner | Follow @JohnCFierce

@DamianFierce: Does anyone know what the "F" in F. Michael Ball stands for? $HSP weirdly won't tell us. | Follow @DamianFierce

> Quantum Genomics raised €11 million in an IPO on the Paris exchange. Release (PDF)

> Sanofi ($SNY) subsidiary Genzyme says its Phase III study of Cerdelga produced promising results for treatment-naive cases of Gaucher disease type 1. Release

> After abandoning plans for an IPO, Dance Biopharm raised $9.5 million in private financing to fund its work on inhalable insulin. More

Medical Device News

@FierceMedDev: ICYMI yesterday: MRI-guided radiation startup files to raise up to $69M in IPO. Article | Follow @FierceMedDev

@VarunSaxena2: FDA agrees to review Pfizer's abuse-deterring opioid candidate. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object. FiercePharmaMarketing article | Follow @EmilyWFierce

> Artificial heart sees most patients to donor heart within a few years. More

> Boston Scientific hands over $600M to settle breach-of-contract Guidant suit with J&J. Article

> Owens & Minor on CEO search ... again. Report

Pharma News

@FiercePharma: Call me Allergan, Actavis says. The buyer will take $AGN's name after their marriage. Release | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Shanghai official linked to $GSK bribery sentenced to 19 years in prison. Article | Follow @CarlyHFierce

> Amphastar pays public agencies rebates after price overdose drug doubles. Story

> Who's the new king of the drug launch hill? Hint: It's all in the Gilead family. Item

> Remicade's U.S. patent rejection could open up early rivalry with Celltrion biosim. Article

> Pharma's top 10 M&A deals of 2014. Special report

Drug Delivery News

> Lupin inks two partnerships to bring lung drugs to overseas markets. Report

> Developer of oral versions of biologic therapies to be purchased by Intrexon. Item

> Actavis divests its drug delivery unit as it barrels toward acquisition of Allergan. News

> Genzyme touts postmarket study of Cerdelga, the only first-line oral therapy for Gaucher disease. Story

> FDA agrees to review Pfizer's abuse-deterring opioid candidate. Article

Diagnostics News

> Lancet study finds that Qiagen's Quantiferon estimates lower rate of TB in China than the traditional test. Story

> Myriad Genetics resolves patent battle with GeneDx over BRCA technology. Item

> Dako joins up with Ono to develop cancer companion Dx. News

> Israel's Pocared receives $15M in funding to commercialize bacteria-identifying computer. Report

> ACT Genomics ropes in $8M for cancer molecular Dx in first private funding round. Article

Pharma Marketing News

> Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object. Story

> Fed-up MD Anderson oncologist jumps on social media to fight drug prices. More

> AstraZeneca picks outspoken (and sometimes critical) prof to join board. Story

> To Pfizer's Chantix, a new JAMA study sounds like 14M potential patients. Article

> AstraZeneca's Pulmicort gets temporary reprieve as judge halts generics launch. Report